Skip to main content
editorial
. 2023 Feb 16;108(7):1721–1723. doi: 10.3324/haematol.2022.282053

Figure 1.

Figure 1.

Design of HBI0101 and new CAR strategies to target B-cell maturation antigen-low multiple myeloma. (A). HBI0101 is a novel chimeric antigen receptor (CAR) that incorporates 4-1BB and CD3ξ signaling moieties, similar to both US Food and Drug Administration-approved B-cell maturation antigen (BCMA) CAR. Cilta-cel comprises two llama-based VHH regions that bind to two different epitopes of BCMA and thereby increase overall binding affinity. (B) To minimize BCMA-low escape, several new CAR designs have been proposed. These include, from left to right, the use of a BCMA HIT receptor, a tandem CAR engaging CD38 and BCMA, a BCMA CAR co-expressed with a CD38 CCR and the use of y-secretase inhibitors to block the shedding of soluble BCMA. Ide-cel: idecabtagene vicleucel; cilta-cel: ciltacabtagene autoleucel; CCR: chimeric co-stimulatory receptor; VHH: variable domain on a heavy-chain; GSI: y-secretase inhibitor; sBCMA: soluble BCMA; HIT: HLA (human leukocyte antigen)-independent T-cell receptor (TCR); Cα/β: constant regions of αβ-TCR.